Read our COVID-19 research and news.

Webinar Technology

Applying humanized mouse models to immune therapy research

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Applying humanized mouse models to immune therapy research

Recorded 16 March 2016



Mouse models have been a mainstay in biomedical research for decades. As these models have become more sophisticated, their application has grown and now includes a wide variety of immunodeficient strains that can be used to examine the in vivo growth of human tumors and to test new cancer treatments. One of the most popular models is the immunodeficient nonobese diabetic severe combined immunodeficiency (NOD scid) gamma (NSG) transgenic mouse line, which can be endowed with a humanized immune system using CD34+ hematopoietic stem cells. Next-generation NSG models that support human myeloid cell proliferation, such as the NSG-SGM3 mouse, can now provide in vivo conditions that better mimic the natural tumor environment. Human tumor tissue or cell lines can be coengrafted into these mouse models, providing a powerful tool for studying the interactions between human immune cells and human cancers. In this webinar we will discuss the latest advances in mouse models for cancer research and how they are being applied to help us understand the pathways and mechanisms involved in new immune therapies.

In this webinar the speakers will:

  • Show comparisons of results from previous and current mouse models carrying reconstituted human immune systems
  • Provide example data from experiments using PD-L1 positive tumors and a cancer cell-line engraftment into a humanized mouse model that was used to test anti-PD1 immune therapy
  • Discuss how mouse models can be used to study human immune responses against leukemia (using primary or genetically modified leukemia cells) and melanoma
  • Answer questions from the live online audience during the broadcast!

The webinar will last approximately 60 minutes.

To learn more about products or technologies related to this webinar, go to:

Speaker bios

Renata Stripecke, Ph.D.

Hannover Medical School
Hannnover, Germany

Dr. Stripecke is currently an associate professor in the Department of Hematology at the Hannover Medical School in Hannover, Germany, and heads the Regenerative Immune Therapies Applied laboratory within the REgenerative BIology and Reconstructive THerapy (REBIRTH) Cluster of Excellence. She obtained her Ph.D. at the European Molecular Biology Laboratory in Heidelberg, Germany, and completed postdoctoral training at the University of California, Los Angeles, Children’s Hospital Los Angeles, and Hamburg University in Hamburg, Germany. She was also an assistant professor at the University of Southern California and at the University of California, Los Angeles. Dr. Stripecke has developed mouse models of leukemia, melanoma, and stem-cell transplantation to test cell therapies preclinically. She designed lentiviral vectors capable of inducing dendritic cell (DC) precursors into personalized cell vaccines tailored for immune regeneration. These lentivirus-induced DCs (iDCs) can be produced under good manufacturing practice-compliant conditions for immunotherapy against cancer and chronic viral infections, and are currently in clinical development. Her laboratory also collaborates with groups interested in testing new vaccine modalities and immunotherapeutics in functionally immune-reconstituted humanized mice.

James Keck, Ph.D.

The Jackson Laboratory
Sacramento, CA

Dr. Keck’s expertise is in animal pharmacology, assay development, drug discovery, target identification, protein expression, and translational research. His work has encompassed several therapeutic areas including oncology, virology, and inflammatory and metabolic diseases. As his career progressed, Dr. Keck was part of a business development team, making presentations to potential corporate partners and interacting with collaborators in industrial and academic centers. He was also a member of a clinical team, coauthoring clinical investigator brochures, Food and Drug Administration (FDA) progress reports, and clinical protocols. Under his leadership, teams of scientists developed high-throughput assays in the areas of oncology, inflammatory and metabolic diseases, viral transcription, and gene function. In his current position at The Jackson Laboratory, he has overall responsibility for the ongoing operational development of the PDX resource, which generates, banks, and distributes patient-derived xenograft (PDX) mouse models of human cancers. The laboratory’s Oncology Preclinical Services team, which offers preclinical efficacy studies using PDX and other models, including humanized (hu)-NSG mice, is also under his direction.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here